Titlebook: Retinal Vein Occlusions; Evidence-Based Manag David J. Browning Book 2012 Springer Science+Business Media New York 2012 Anti-VEGF drugs.Ele

medium

David J. Browning MD, PhDrgestellt. Abschlie?end wird anhand von drei Fallbeispielen die Komplexit?t und Widersprüchlichkeit von medialer Globalisierung nachvollziehbar dargestellt. Insgesamt zielt der Band "Globalisierung der Medien" so darauf ab, differenziert in eine Auseinande978-3-531-13998-2978-3-322-80452-5Series ISSN 2524-3160 Series E-ISSN 2524-3179

有幫助

Offensive

人類

the parallel progress in understanding of disease mechanisms. Complete with case studies, this text is perfect for retina specialists, ophthalmologists, optometrists, and residents and fellows in these fields. .978-1-4939-5180-2978-1-4614-3439-9

隱藏

The Clinical Picture and Natural History of Retinal Vein Occlusions, history of RVOs may change over time with changes in population demographics (e.g., the recent epidemic of obesity in industrialized nations) and general medical care. Understanding the natural history of RVOs is important because it informs judgment of the effectiveness of therapies.50

蠟燭

Ancillary Testing in the Management of Retinal Vein Occlusions,e of a patient to make obtaining it worthwhile. There is an inherent conflict of interest in fee-for-service systems of health care (e.g., in the United States). The ophthalmologist profits by ordering more ancillary tests. Therefore, the topic is not only important to discuss but also sensitive.11

急急忙忙

Ischemia and Retinal Vein Occlusions, the terms nonischemic and ischemic to describe RVOs.22 The classification of RVO based on ischemia is covered in ., as well as the controversies and confusion surrounding the various definitions of ischemia. In this chapter, the perspective is, instead, practical and clinical.

Moderate

Treatment of Retinal Vein Occlusions,mized controlled clinical trial – but have not been rejected either. These treatments are also covered here and clearly identified as provisional. A table of abbreviations used in this chapter follows (Table 13.1). The abbreviations are spelled out at their first occurrence.

Enzyme

Book 2012dema associated with central retinal vein occlusion (CRVO), no effective therapy existed until 2009, despite decades of research and failed pilot therapies. This comprehensive, illustrated text integrates recent advances in treatments with the parallel progress in understanding of disease mechanisms

盡責(zé)

Systemic and Ocular Associations of Retinal Vein Occlusions, ophthalmologist naturally considers using laser treatment, intravitreal injections, or surgery in patients with RVO. However, optimizing the systemic and ocular factors that influence RVO is prudent, may reduce the risk of subsequent RVO in the same or the fellow eye, and may reduce the severity of subsequent problems in the affected eye.205